Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 28NIH 3INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Gastrointestinal 1Breast 1

Conditions

Multiple Myeloma 21Uveal Melanoma 5Melanoma 4Lymphoma 3Leukemia, Myeloid, Acute 3Leukemia 3Hodgkin Disease 3Recurrence 2Rectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Carcinoma, Hepatocellular 2Anemia, Refractory, with Excess of Blasts 2Vipoma 1Stomach Neoplasms 1Somatostatinoma 1Pheochromocytoma 1Neoplasms, Plasma Cell 1Lymphoma, T-Cell, Cutaneous 1Liver Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1Leukemia, B-Cell 1Insulinoma 1Hematologic Neoplasms 1

Interventions

Dexamethasone 64Lenalidomide 34pomalidomide 33Cyclophosphamide 33Rituximab 31Bortezomib 29venetoclax 27fludarabine 26Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 16Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Injections 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × Melphalan × Clear all
NCT04150042 2026-01-29

SHARON

General Oncology, Inc.

Phase 1 Recruiting
24 enrolled
BreastGastrointestinal

Breast Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Recurrence

NCT02206425 2023-10-31

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Oncotherapeutics

Phase 1/2 Completed
45 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡